Please login to the form below

Not currently logged in
Email:
Password:

Sanofi fires off another lawsuit against a Lantus biosimilar

Alleges patent infringement by Merck & Co’s biosimilar version filed in the US last month
Sanofi

Sanofi has rushed to the defence of blockbuster basal insulin product Lantus in the US once again, filing a patent infringement lawsuit against Merck & Co.

The suit has been prompted by Merck's filing for approval of a biosimilar version of Lantus (insulin glargine) called MK-1293 last month, and alleges infringement of 10 patents covering the drug as well as Lilly's SoloStar pen injector device.

The case looks like a re-run of Sanofi's earlier lawsuit against Eli Lilly, which was settled a year ago after Lilly agreed to pay royalties to the French pharma group in exchange for a license to certain Sanofi patents.

Lilly also agreed to hold off on launching its pen injector formulation of the Basaglar product - already on the market as Abasaglar in Europe - until 15 December 2016. It was free to move ahead with the launch of a vial formulation of the biosimilar, although vials are thought to represent only around a third of total Lantus sales.

Lantus made more than $7bn in sales last year but is already showing the effects of competition from biosimilars and other branded basal insulin rivals such as Novo Nordisk's Levemir (insulin detemir), with sales dropping 11%.

That trend continued with another 15% decline in the first half of 2016, with the falls not fully compensated by growth for longer-acting insulin glargine follow-up Toujeo.

Nevertheless, every additional month of exclusivity gained in the US market limits the decline in Lantus and allows Toujeo and Sanofi's other new products such as cholesterol-lowering therapy Praluent (alirocumab) to gain ground.

Merck (known as MSD outside the US), which developed its biosimilar in partnership with Samsung Bioepis, has also filed for approval of the drug in Europe.

Article by
Phil Taylor

19th September 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics